Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 20/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabiporide SCHEMBL1286649 | 0.99 | SLC9A1 (0.98) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| Sabiporide SCHEMBL4901735 | 0.98 | SLC9A1 (0.96) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| Sabiporide SCHEMBL27472449 | 0.94 | SLC9A1 (0.89) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14491835 | 0.92 | SLC9A1 (0.85) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5950962 | 0.85 | SLC9A1 (0.73) | SLC9A1CYP2C19CYP3A4CYP2C9ADRA1D | |
| SCHEMBL6137374 | 0.85 | SLC9A1 (0.73) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6137426 | 0.83 | SLC9A1 (0.71) | SLC9A1CYP2C19CYP3A4CYP2C9CYP2D6 | |
| Sabiporide SCHEMBL29385812 | 0.82 | SLC9A1 (0.70) | SLC9A1CYP2C19CYP3A4 | |
| Sabiporide SCHEMBL1286662 | 0.82 | SLC9A1 (0.70) | SLC9A1CYP2C19CYP3A4 | |
| SCHEMBL7982477 | 0.82 | SLC9A1 (0.69) | SLC9A1CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818047-A2 | Oral administration form for difficulty soluble basic active ingredients | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | claimed |
| US-20060035862-A1 | Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-16 | — | — | US | claimed |
| US-6982256-B2 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-01-03 | — | — | US | claimed |
| EP-1165534-B1 | BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-02-02 | — | — | EP | claimed |
| EP-1427419-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-06-16 | — | — | EP | claimed |
| US-20030069207-A1 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-10 | — | — | US | claimed |
| WO-2003022281-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-20 | — | — | WO | claimed |
| US-8512748-B2 | Oral administering of active materials; pH sensitivity; multilayer; core; insulation layer; water insoluble polymer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| EP-1362030-B1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-04-11 | — | — | EP | disclosed |
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-10-02 | — | — | US | disclosed |
| US-20080069873-A1 | Controlled release system and method for manufacturing the same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080025919-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-01-31 | — | — | US | disclosed |
| EP-1818047-A2 | Oral administration form for difficulty soluble basic active ingredients | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20030069207-A1 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-10 | — | — | US | disclosed |
| WO-2003022281-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022281-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022281-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-26 | — | — | US | disclosed |
| WO-2002064563-A1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064563-A1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025919-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | SLC9A1, SLC9A2, SLC9A3 | SLC9A1 1/4885CYP2C19 401/4885CYP3A4 1789/4885 |
| US-20030069207-A1 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | GIPR, SLC11A2, SLC10A2 | SLC9A1 654/4885CYP2C19 16/4885CYP3A4 127/4885 |
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | SLC9A1, SLC9A2, SLC9A3 | SLC9A1 1/4885CYP2C19 401/4885CYP3A4 1789/4885 |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | SLC9A1, SLC9A3, SLC9A2 | SLC9A1 1/4885CYP2C19 507/4885CYP3A4 2281/4885 |
| US-20060035862-A1 | Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | SLC11A2, SLC7A1, SLC2A9 | SLC9A1 620/4885CYP2C19 29/4885CYP3A4 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.